The US Food and Drug Administration (FDA) has approved GSK's British drug Nelcarmi for the treatment of non-small cell lung cancer, reports the Financial Times. The drug became a central asset in the purchase of the American biotechnology company Nuvalent for $10.6 billion in June. According to Jefferies analysts, peak sales for the purchased pipeline could range from $5 billion to $7 billion.